GLP-1 Agonists and Heart Health: Which Drugs Offer Cardioprotection?

Last Updated: March 2026

Glucagon-like peptide-1 (GLP-1) receptor agonists have revolutionized the treatment of type 2 diabetes and chronic weight management. Beyond their well-established effects on blood sugar control and body weight, these medications have demonstrated significant, durable benefits for cardiovascular health. In the landmark SELECT trial, semaglutide (Wegovy 2.4 mg) reduced the risk of major adverse cardiovascular events (MACE) by 20% in adults with established cardiovascular disease and overweight or obesity without diabetes (New England Journal of Medicine, 2023). This finding cemented GLP-1s as a critical tool in comprehensive cardiovascular risk reduction.

The cardiovascular benefits of GLP-1 agonists extend beyond weight loss, encompassing improvements in blood pressure, lipid profiles, and systemic inflammation. However, not all GLP-1 agonists have the same level of evidence for direct cardioprotection. This guide breaks down the science behind which GLP-1 medications protect the heart, how they do it, and for which patient populations.

The Broad Cardiovascular Impact of GLP-1 Agonists

The heart-protective effects of GLP-1 agonists are multifaceted. While weight loss itself is a powerful cardiovascular intervention, GLP-1s appear to confer benefits independently of, or in addition to, their impact on body weight. Mechanisms include:

• Blood Pressure Reduction: GLP-1s can lower both systolic and diastolic blood pressure.
• Improved Lipid Profiles: They may reduce levels of triglycerides and low-density lipoprotein (LDL) cholesterol.
• Anti-inflammatory Effects: GLP-1s can reduce markers of systemic inflammation, which contribute to atherosclerosis.
• Endothelial Function: They may improve the function of the blood vessel lining.
• Direct Myocardial Effects: Some research suggests direct protective effects on heart muscle cells.

These benefits are crucial, particularly since patients in cardiovascular outcome trials (CVOTs) for GLP-1s were typically already receiving standard-of-care cardiovascular medications, including statins, antiplatelet agents, and antihypertensives. The addition of GLP-1s demonstrated further, incremental risk reduction.

Semaglutide: The Standard for Cardioprotection

Semaglutide stands out with the strongest and most recent evidence for broad cardiovascular protection. Available as Ozempic (for type 2 diabetes) and Wegovy (for chronic weight management), this GLP-1 agonist has demonstrated benefits across different patient populations.

SELECT Trial: Semaglutide for Overweight/Obesity with CVD

The Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial was a pivotal study that enrolled 17,604 adults who were overweight or obese (BMI ≥27 kg/m²) and had established cardiovascular disease, but without type 2 diabetes. Participants received once-weekly semaglutide 2.4 mg or placebo for an average of 3.3 years.

The trial’s primary endpoint, a composite of cardiovascular death, non-fatal myocardial infarction (heart attack), or non-fatal stroke (MACE), occurred in 6.5% of participants receiving semaglutide compared to 8.0% of those receiving placebo. This translated to a 20% relative risk reduction in MACE with semaglutide. Specifically:

• Cardiovascular death was reduced by 15%.
• Non-fatal myocardial infarction was reduced by 28%.
• Non-fatal stroke was reduced by 7%.

This evidence led to the FDA approval of Wegovy (semaglutide 2.4 mg) in March 2024 to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and either obesity or overweight. The FDA stated, “Wegovy is now the first weight management drug to also be approved to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight.” This marks a significant milestone, making semaglutide the only GLP-1 agonist with an indication for primary cardiovascular event reduction in patients without diabetes.

SUSTAIN 6 Trial: Semaglutide for Type 2 Diabetes with CVD

Prior to SELECT, the Cardiovascular Outcomes Results Trial With Semaglutide Once Weekly (SUSTAIN 6) trial, published in 2016, examined semaglutide’s cardiovascular safety and efficacy in patients with type 2 diabetes who had a high cardiovascular risk. This trial included 3,297 patients randomized to semaglutide or placebo. SUSTAIN 6 demonstrated a 26% reduction in the composite MACE endpoint with semaglutide versus placebo.

While conducted in a type 2 diabetes population, SUSTAIN 6 provided early evidence of semaglutide’s cardiovascular benefits, setting the stage for the broader implications seen in SELECT.

Liraglutide: Pioneering Cardiovascular Benefits

Liraglutide, marketed as Victoza (for type 2 diabetes) and Saxenda (for chronic weight management), was the first GLP-1 agonist to demonstrate a significant reduction in cardiovascular events.

LEADER Trial: Liraglutide for Type 2 Diabetes with CVD

The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, published in 2016, was a landmark study involving 9,340 patients with type 2 diabetes at high risk for cardiovascular events. Participants received liraglutide or placebo for a median of 3.8 years.

The LEADER trial showed a 13% reduction in the primary composite MACE endpoint (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in the liraglutide group compared to the placebo group. Specifically:

• Cardiovascular death was reduced by 22%.
• All-cause death was reduced by 15%.

These results established liraglutide as a critical agent for cardiovascular risk reduction in patients with type 2 diabetes and high cardiovascular risk.

Dulaglutide: Sustained and Broad Protection

Dulaglutide, known as Trulicity, is another once-weekly GLP-1 agonist with robust cardiovascular outcome data.

REWIND Trial: Dulaglutide for Type 2 Diabetes with CVD Risk Factors

The Researching Cardiovascular Events With a Weekly GLP-1 Receptor Agonist in Patients With Type 2 Diabetes (REWIND) trial, published in 2019, uniquely focused on a broader population of 9,901 patients with type 2 diabetes, most of whom had established cardiovascular risk factors but not necessarily established cardiovascular disease. Participants received dulaglutide or placebo for a median of 5.4 years.

REWIND demonstrated a 12% reduction in the primary composite MACE endpoint with dulaglutide. A notable finding from REWIND was the significant reduction in stroke risk, which was 24% lower in the dulaglutide group. The trial’s longer duration and inclusion of a population with cardiovascular risk factors but not necessarily established disease highlighted dulaglutide’s potential for cardiovascular protection in a wider range of patients with type 2 diabetes.

Tirzepatide (Dual GIP/GLP-1 Agonist): Emerging Cardiovascular Data

Tirzepatide, marketed as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management), is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. While not a pure GLP-1 agonist, its GLP-1 activity is significant, and it has shown impressive results in blood glucose control and weight loss.

Direct cardiovascular outcome data from dedicated MACE trials for tirzepatide in overweight/obesity without diabetes are currently emerging. However, secondary endpoints and pooled analyses from the SURPASS clinical trial program (for type 2 diabetes) and SURMOUNT (for obesity) have consistently shown positive impacts on cardiovascular risk factors, including:

• Significant reductions in systolic and diastolic blood pressure.
• Improvements in lipid profiles, including reductions in triglycerides and LDL cholesterol.
• Reductions in inflammatory markers.

Dedicated cardiovascular outcome trials for tirzepatide are underway. The SURMOUNT-MMO (MACE Mounjaro Obesity) trial and the SUMMIT trial (examining heart failure with preserved ejection fraction) are specifically designed to assess tirzepatide’s direct impact on MACE and other cardiovascular endpoints in patients with obesity or overweight, with and without type 2 diabetes. The SURMOUNT-MMO trial, for instance, is evaluating the impact of tirzepatide on MACE in adults with obesity or overweight and established atherosclerotic cardiovascular disease, similar to the SELECT trial population. These results are highly anticipated and will provide definitive data on tirzepatide’s direct cardiovascular event reduction capabilities.

Comparison of GLP-1 Agonists for Cardiovascular Protection

Note: MACE = Major Adverse Cardiovascular Events (composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke).

Ranking by Evidence Strength for Cardiovascular Protection

Based on the available evidence, GLP-1 agonists can be ranked by the strength and breadth of their proven cardiovascular benefits:

1. Semaglutide (Wegovy 2.4 mg): Holds the strongest, most direct evidence for reducing MACE in individuals with established cardiovascular disease and overweight or obesity, independent of type 2 diabetes. Its FDA approval for this specific indication underscores its leading position. Semaglutide (Ozempic) also has strong evidence for T2D patients.
2. Liraglutide (Victoza) & Dulaglutide (Trulicity): Both have robust evidence for reducing MACE in patients with type 2 diabetes at high cardiovascular risk, or with established cardiovascular disease. They were pivotal in establishing the class-effect for cardiovascular benefits in T2D. Liraglutide has a more pronounced reduction in CV death, while dulaglutide showed impressive stroke reduction and efficacy in a broader T2D population.
3. Tirzepatide (Mounjaro/Zepbound): While showing significant improvements in cardiovascular risk factors and likely to demonstrate direct